ImmunityBio, Inc. (IBRX)

ImmunityBio, Inc. (IBRX) Healthcare & Pipeline Overview

ImmunityBio, Inc. pioneers next-generation immunotherapies and vaccines, targeting cancers and infectious diseases. The company leverages its diverse platform of antibody cytokine fusion proteins, cell therapies, and vaccine technologies to develop novel treatments. With multiple clinical trials underway, ImmunityBio aims to address unmet needs in oncology and infectious disease management.

What Is the Investment Thesis for IBRX?

ImmunityBio presents a notable research candidate within the biotechnology sector, driven by its innovative immunotherapy platforms and a robust pipeline of clinical-stage assets. The company's focus on developing therapies and vaccines for cancers and infectious diseases addresses significant unmet medical needs, offering substantial market potential. With a market capitalization of $9.44B, ImmunityBio is positioned to capitalize on its ongoing Phase II and Phase III clinical trials, particularly in areas such as bladder, pancreatic, and lung cancers, as well as treatments for SARS-CoV-2 and HIV. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's high gross margin of 93.8% indicates strong pricing power and efficient operations. However, the negative profit margin of -606.2% highlights the significant R&D expenses associated with clinical-stage development. Upcoming clinical trial results and potential FDA approvals represent key catalysts for future growth.

Based on FMP financials and quantitative analysis

IBRX Key Highlights

• Market capitalization of $9.44B reflects investor confidence in ImmunityBio's pipeline and technology.
• Gross margin of 93.8% indicates strong potential for profitability as products reach commercialization.
• Negative profit margin of -606.2% highlights ongoing investment in research and development.
• Beta of 0.06 suggests low volatility compared to the broader market.
• Focus on immunotherapy and cell therapy platforms positions ImmunityBio in a high-growth area of biotechnology.

Who Are IBRX's Competitors?

IBRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IBRX's Key Strengths?

• Innovative immunotherapy and vaccine platforms.
• Robust clinical-stage pipeline.
• Strong intellectual property portfolio.
• Strategic collaborations with leading institutions.

What Are IBRX's Weaknesses?

• High R&D expenses.
• Negative profit margin.
• Reliance on clinical trial success.
• Regulatory risks.

What Could Drive IBRX Stock Higher?

• Clinical trial results for bladder cancer treatment expected in Q4 2026.
• FDA submission for pancreatic cancer therapy anticipated in H1 2027.
• Continued progress in Phase II trials for SARS-CoV-2 vaccine.
• Expansion of strategic collaborations with research institutions.

What Are the Key Risks for IBRX?

• Financial-distress signal — its Altman Z-Score of -8.38 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results could delay or halt product development.
• Failure to obtain regulatory approvals could impact commercialization plans.
• Competition from established pharmaceutical companies could limit market share.
• High R&D expenses could strain financial resources.

What Are the Growth Opportunities for IBRX?

• Growth opportunity 1: Expansion into new therapeutic areas represents a significant growth opportunity for ImmunityBio. By leveraging its immunotherapy platforms, the company can target additional cancers and infectious diseases, broadening its market reach and diversifying its revenue streams. The global market for cancer therapies is projected to reach hundreds of billions of dollars by 2030, offering substantial potential for ImmunityBio to capture market share with its innovative treatments. Timeline: Ongoing, with new clinical trials planned for 2027-2028.
• Growth opportunity 2: Strategic partnerships and collaborations can accelerate ImmunityBio's growth by providing access to new technologies, funding, and market expertise. Collaborations with pharmaceutical companies, research institutions, and government agencies can enhance the company's R&D capabilities and facilitate the commercialization of its products. The value of strategic partnerships in the biotechnology industry is estimated to be in the billions of dollars annually. Timeline: Ongoing, with potential new partnerships in 2026-2027.
• Growth opportunity 3: Successful clinical trial outcomes and regulatory approvals are critical for ImmunityBio's growth. Positive data from Phase II and Phase III trials can validate the efficacy and safety of its therapeutic candidates, leading to FDA approval and commercial launch. The market value of newly approved cancer therapies can reach billions of dollars annually. Timeline: Upcoming, with key clinical trial results expected in late 2026 and early 2027.
• Growth opportunity 4: Geographic expansion into international markets offers another avenue for growth. By expanding its presence in Europe, Asia, and other regions, ImmunityBio can tap into new patient populations and revenue streams. The global market for cancer therapies is growing rapidly in emerging economies. Timeline: Potential expansion into Europe and Asia in 2027-2028.
• Growth opportunity 5: Development of next-generation immunotherapy platforms can provide a competitive advantage for ImmunityBio. By investing in research and development of innovative technologies, the company can create more effective and targeted therapies for cancer and infectious diseases. The market for next-generation immunotherapies is expected to grow significantly in the coming years. Timeline: Ongoing, with new research initiatives planned for 2026-2027.

What Opportunities Does IBRX Have?

• Expansion into new therapeutic areas.
• Strategic partnerships and collaborations.
• Successful clinical trial outcomes and regulatory approvals.
• Geographic expansion into international markets.

What Threats Does IBRX Face?

• Competition from established pharmaceutical companies.
• Failure to obtain regulatory approvals.
• Unfavorable clinical trial results.
• Changes in healthcare regulations.

What Are IBRX's Competitive Advantages?

• Proprietary immunotherapy and vaccine platforms.
• Extensive patent portfolio protecting its technologies.
• Clinical-stage pipeline with multiple therapeutic candidates.
• Strategic collaborations with leading research institutions and companies.

What Does IBRX Do?

Founded in 2014 and based in San Diego, California, ImmunityBio, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies and vaccines that bolster the body's natural immune system to combat cancer and infectious diseases. The company's core focus lies in harnessing the power of immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. These platforms are designed to stimulate and enhance the immune response, enabling the body to effectively target and eliminate diseased cells. ImmunityBio's pipeline features a range of therapeutic agents currently undergoing Phase II and Phase III clinical trials. These agents target a variety of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens such as SARS-CoV-2 and HIV. The company has established strategic collaborations with institutions such as the National Cancer Institute and the National Institute of Deafness and Communication Disorders, as well as with companies like Amyris, Inc., to advance its research and development efforts. Additionally, ImmunityBio has entered into license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc., further expanding its access to innovative technologies and therapeutic candidates. ImmunityBio's mission is to transform the treatment landscape for cancer and infectious diseases by developing and delivering groundbreaking immunotherapies and vaccines.

What Products and Services Does IBRX Offer?

• Develops immunotherapies and vaccines for cancers and infectious diseases.
• Offers antibody cytokine fusion proteins to enhance immune response.
• Creates synthetic immunomodulators to regulate immune system activity.
• Utilizes vaccine technologies to prevent and treat infectious diseases.
• Develops natural killer cell therapies to target cancer cells.
• Harnesses adaptive (T cell) immune systems for targeted therapies.
• Conducts Phase II and Phase III clinical trials for various therapeutic agents.

How Does IBRX Make Money?

• Develops and patents novel immunotherapy and vaccine technologies.
• Conducts clinical trials to demonstrate the safety and efficacy of its therapeutic candidates.
• Seeks regulatory approvals from agencies such as the FDA.
• Commercializes approved products through direct sales and marketing or partnerships.

What Industry Does IBRX Operate In?

ImmunityBio operates within the rapidly evolving biotechnology industry, which is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by advancements in genomics, proteomics, and personalized medicine. Immunotherapy, in particular, has emerged as a promising approach to cancer treatment, with significant investments and clinical successes. ImmunityBio's focus on immunotherapy and cell therapy platforms aligns with these trends, positioning the company to compete with established players and emerging innovators in the field. The company's success will depend on its ability to navigate the complex regulatory landscape, secure funding for ongoing clinical trials, and demonstrate the efficacy and safety of its therapeutic candidates.

Who Are IBRX's Key Customers?

• Patients with cancer and infectious diseases.
• Healthcare providers who prescribe and administer ImmunityBio's therapies.
• Hospitals and clinics that use ImmunityBio's products.
• Research institutions and government agencies that collaborate with ImmunityBio.

ROE 139%Key Financial Metrics

Return on equity for ImmunityBio, Inc. stands at 138.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.5%, the inverse of the P/E and a quick read on earnings relative to price.

How ImmunityBio, Inc. Is Valued

ImmunityBio, Inc. carries a market capitalization of $9.44B, placing it in the mid-cap category. Relative to its peer group, IBRX's quantitative score of 10/100 is below the peer average of 74/100.

F-Score 3/9Financial Health

ImmunityBio, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.38 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project ImmunityBio, Inc. revenue of about $222.3M for fiscal 2026, with EPS near $-0.85.

IBRX Financials

IBRX Latest News

IBRX Analyst Consensus

IBRX MoonshotScore

Latest ImmunityBio, Inc. Analysis

ImmunityBio, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources